BioSpace News Archive

Drug Development

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

Onward Therapeutics SA announced that the phase 1 clinical trial of OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints is in progress.

January 24, 2024
·
3 min read
Sirona Biochem Corporate Update January 2024

We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem’s path forward.

January 24, 2024
·
6 min read
Business

Samsung Biologics Reports Fourth Quarter & Fiscal Year 2023 Financial Results

Samsung Biologics announced robust financial results for the fourth quarter and fiscal year 2023.

January 24, 2024
·
5 min read
Drug Development

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Abivax SA announces the organization of a virtual KOL Investor Event on Tuesday, February 6, 2024, at 2:00 p.m. EST.

January 24, 2024
·
2 min read
Medivir to present at the Redeye Fight Cancer Day - January 24, 2024

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Fight Cancer Day, January 24, 2024.

January 24, 2024
·
1 min read
PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions

PRISM BioLab, Co. Ltd., a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction targets, announced a 1.5 billion yen fundraise.

January 24, 2024
·
3 min read
Drug Development

Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

Ascletis Pharma Inc. announces dosing of the first patient in Phase III clinical trial of ASC40 for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University.

January 24, 2024
·
2 min read
BioCapital

Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors

Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced the Company published a research article with NAR Cancer.

January 24, 2024
·
3 min read
Deals

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases

Kyowa Kirin Co., Ltd. a Japan-based global specialty pharmaceutical company discovering and developing novel medicines utilizing the latest biotechnology, and Orchard Therapeutics plc, a global gene therapy leader, announced Kyowa Kirin has successfully completed the acquisition of Orchard Therapeutics.

January 24, 2024
·
9 min read
Policy

Biosion Announces FDA Clearance of IND Application for BSI-082, a Novel Anti-SIRPα Monoclonal Antibody

Biosion USA, Inc., a global clinical-stage R&D biotechnology company, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for BSI-082, a novel anti-SIRPα monoclonal antibody candidate.

January 24, 2024
·
2 min read